Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.50 |
| ▸ | LMNA | P02545 | 3/20 | 0.50 |
| ▸ | NPC1 | O15118 | 2/20 | 0.50 |
| ▸ | RAB9A | P51151 | 2/20 | 0.50 |
| ▸ | TSHR | P16473 | 3/20 | 0.47 |
| ▸ | TP53 | P04637 | 2/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | NAAA | Q02083 | 2/20 | 0.44 |
| ▸ | PLA2G4B | P0C869 | 1/20 | 0.44 |
| ▸ | PPARA | Q07869 | 4/20 | 0.44 |
| ▸ | PPARG | P37231 | 3/20 | 0.44 |
| ▸ | GPR88 | Q9GZN0 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8081509 | 0.98 | SMN1; SMN2 (0.51) | SMN1; SMN2LMNANPC1RAB9ATSHR | |
| SCHEMBL8072241 | 0.98 | SMN1; SMN2 (0.51) | SMN1; SMN2LMNANPC1RAB9ATSHR | |
| SCHEMBL8081132 | 0.98 | SMN1; SMN2 (0.51) | SMN1; SMN2LMNANPC1RAB9ATSHR | |
| SCHEMBL5508979 | 0.98 | SMN1; SMN2 (0.51) | SMN1; SMN2LMNANPC1RAB9ATSHR | |
| SCHEMBL10639062 | 0.98 | SMN1; SMN2 (0.51) | SMN1; SMN2LMNANPC1RAB9ATSHR | |
| SCHEMBL8081523 | 0.98 | SMN1; SMN2 (0.51) | SMN1; SMN2LMNANPC1RAB9ATSHR | |
| SCHEMBL3485833 | 0.95 | TSHR (0.46) | SMN1; SMN2LMNANPC1RAB9ATSHR | |
| SCHEMBL8084866 | 0.88 | PPARA (0.47) | SMN1; SMN2LMNACYP3A4ALDH1A1PPARA | |
| SCHEMBL17724542 | 0.88 | PPARA (0.47) | SMN1; SMN2LMNACYP3A4ALDH1A1PPARA | |
| SCHEMBL10698580 | 0.87 | LMNA (0.48) | SMN1; SMN2LMNANPC1RAB9ATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-56120687-A | — | — | None | — | — | JP | disclosed |
| US-11083717-B2 | Compositions and methods for drug sensitization of parasites | THE TEXAS A&M UNIVERSITY SYSTEM (US) | 2021-08-10 | — | — | US | disclosed |
| US-20200138796-A1 | COMPOSITIONS AND METHODS FOR DRUG SENSITIZATION OF PARASITES | THE TEXAS A&M UNIVERSITY SYSTEM | 2020-05-07 | — | — | US | disclosed |
| US-20190314381-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF MYCOBACTERIA | THE TEXAS A&M UNIVERSITY SYSTEM | 2019-10-17 | — | — | US | disclosed |
| US-10300071-B2 | Compositions and methods for inhibition of mycobacteria | THE TEXAS A&M UNIVERSITY SYSTEM (US) | 2019-05-28 | — | — | US | disclosed |
| US-20170065601-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF MYCOBACTERIA | THE TEXAS A&M UNIVERSITY SYSTEM | 2017-03-09 | — | — | US | disclosed |
| EP-2155692-B1 | NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS | HOFFMANN LA ROCHE (CH) | 2015-06-17 | — | — | EP | disclosed |
| US-8026362-B2 | Non-nucleoside reverse transcriptase inhibitors | ROCHE PALO ALTO LLC (US) | 2011-09-27 | — | — | US | disclosed |
| EP-2155692-A1 | NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS | F. Hoffmann-Roche AG (CH) | 2010-02-24 | — | — | EP | disclosed |
| US-20090076045-A1 | Non-nucleoside reverse transcriptase inhibitors | ROCHE PALO ALTO LLC | 2009-03-19 | — | — | US | disclosed |
| WO-2008145562-A1 | NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2008-12-04 | — | — | WO | disclosed |
| EP-0758013-B1 | Liquid crystalline optical film, compensating film for liquid crystal display and liquid crystal display | NIPPON OIL CO LTD (JP) | 2000-10-11 | — | — | EP | disclosed |
| US-5855971-A | Liquid crystalline optical film, compensating film for liquid crystal display comprising the liquid crystalline optical film, and liquid crystal display having the compensating film | NIPPON OIL COMPANY, LIMITED (JP) | 1999-01-05 | — | — | US | disclosed |
| EP-0758013-A1 | Liquid crystalline optical film, compensating film for liquid crystal display and liquid crystal display | NIPPON OIL COMPANY, LIMITED (JP) | 1997-02-12 | — | — | EP | disclosed |
| JP-S56120687-A | CEPHALOSPORIN DERIVATIVE AND ITS PREPARATION | TAKEDA CHEM IND LTD | 1981-09-22 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10300071-B2 | Compositions and methods for inhibition of mycobacteria | ME3, PGLS, GNPAT | SMN1; SMN2 4812/4885LMNA 1692/4885NPC1 1297/4885 |
| US-20190314381-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF MYCOBACTERIA | ME3, PGLS, GNPAT | SMN1; SMN2 4812/4885LMNA 1692/4885NPC1 1297/4885 |
| US-20200138796-A1 | COMPOSITIONS AND METHODS FOR DRUG SENSITIZATION OF PARASITES | ABCC1, SLC11A2, ABCG2 | SMN1; SMN2 4367/4885LMNA 2846/4885NPC1 1324/4885 |
| US-11083717-B2 | Compositions and methods for drug sensitization of parasites | ABCC1, SLC11A2, ABCG2 | SMN1; SMN2 4367/4885LMNA 2846/4885NPC1 1324/4885 |
| US-20090076045-A1 | Non-nucleoside reverse transcriptase inhibitors | HPRT1, XDH, REV1 | SMN1; SMN2 2429/4885LMNA 2236/4885NPC1 546/4885 |
| US-20170065601-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF MYCOBACTERIA | ME3, PGLS, GNPAT | SMN1; SMN2 4812/4885LMNA 1692/4885NPC1 1297/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.